Abstract
Get full access to this article
View all access options for this article.
References
1.National Cancer Institute . History of the National Cancer Institute , https://www.cancer.gov/about-nci/overview/history (2015 , accessed 16 January 2020 ).
2.National Institutes of Health . History of congressional appropriations, fiscal years 2000 - 2019 , https://officeofbudget.od.nih.gov/pdfs/FY19/Approp%20History%20by%20IC%20FY%202000%20-%20FY%202019%20(V3).pdf (2019 , accessed 16 January 2020 ).
3.PhRMA . The biopharmaceutical research and development , http://phrma-docs.phrma.org/sites/default/files/pdf/rd_brochure_022307.pdf (2015 , accessed 16 January 2020 ).
4.
Mensah
GA
Wei
GS
Sorlie
PD
, et al . Decline in cardiovascular mortality: possible causes and implications . Circ Res 2017 ; 120 (2 ): 366 –380 .
5.
Bach
PB.
Limits on Medicare’s ability to control rising spending on cancer drugs . N Engl J Med 2009 ; 360 (6 ): 626 –633 .
6.IQVIA Institute . Global oncology trends 2018 , https://www.iqvia.com/insights/the-iqvia-institute/reports/global-oncology-trends-2018 (2018 , accessed 16 January 2020 ).
7.IQVIA Institute . Global oncology trends 2019 , https://www.iqvia.com/insights/the-iqvia-institute/reports/global-oncology-trends-2019 (2019 , accessed 16 January 2020 ).
8.
Hsiue EH-C Moore
TJ
Alexander
GC
. Estimated costs of pivotal trials for U.S. Food and Drug Administration (FDA)-approved cancer drugs, 2015-2017 . Clin Trials 2020 ; 17 (2 ): 119 –125 .
9.Blueprint Medicines . Blueprint Medicines announces FDA approval of AYVAKIT™ (avapritinib) for the treatment of adults with unresectable or metastatic PDGFRA exon 18 mutant gastrointestinal stromal tumor , http://ir.blueprintmedicines.com/news-releases/news-release-details/blueprint-medicines-announces-fda-approval-ayvakittm-avapritinib (2020 , accessed 16 January 2020 ).
10.
DiMasi
JA
Grabowski
HG
Hansen
RW
. Innovation in the pharmaceutical industry: new estimates of R&D costs . J Health Econ 2016 ; 47 : 20 –33 .